Patents by Inventor Stephen Lyle Briggs

Stephen Lyle Briggs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7109229
    Abstract: The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: September 19, 2006
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Kelly Wayne Furness, Sushant Malhotra, Stephen Lyle Briggs, Harold Burns Brooks, David K yes Clawson, Concepcion Sanchez-Martinez, Faming Zhang, Guoxin Zhu
  • Publication number: 20040048915
    Abstract: The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).
    Type: Application
    Filed: February 7, 2003
    Publication date: March 11, 2004
    Inventors: Thomas Albert Engler, Kelly Wayne Furness, Sushant Malhotra, Stephen Lyle Briggs, Harold Burns Brooks, David Keyes Clawson, Concepcion Sanchez-Martinez, Faming Zhang, Guoxin Zhu
  • Publication number: 20030068802
    Abstract: Provided are methods of purifying and crystallizing Streptococcus pneumoniae acyl carrier protein synthase (AcpS) enzyme, crystals of AcpS, the use of such crystals to determine the three-dimensional structure of AcpS enzymes, and the three-dimensional structure of AcpS. The three-dimensional crystal structure of AcpS can be used in medical diagnostics to produce antibodies that permit detection of Streptococcus pneumoniae both in vitro and in vivo. The three-dimensional crystal structure of AcpS can also be used in pharmaceutical discovery and development to identify and design compounds that inhibit the biochemical activity of AcpS enzyme in bacteria. Inhibitory compounds identified in this way can be optimized by structure/activity studies to develop antibacterial pharmaceutical compounds useful for the prevention or treatment of bacterial infections.
    Type: Application
    Filed: June 29, 2001
    Publication date: April 10, 2003
    Inventors: Nicholas Yuri Chirgadze, Stephen Lyle Briggs, Genshi Zhao, Kelly Ann McAllister